An open-label randomized phase II study of two different dosing regimens of capecitabine in combination with intravenous docetaxel (Q3W) in patients with locally advanced and/or metastatic breast cancer
Latest Information Update: 23 Nov 2009
At a glance
- Drugs Capecitabine (Primary) ; Docetaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Roche
- 21 Nov 2009 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
- 19 Jan 2006 New trial record.